Teladoc Health expands its Comprehensive Weight Care program, offering employers access to GLP-1 medications and support for employees' weight management.
Quiver AI Summary
Teladoc Health has announced an expansion of its Comprehensive Weight Care program, allowing employers to offer FDA-approved GLP-1 medications while managing medication costs predictably. This new offering enables employers to subsidize GLP-1 medications from Eli Lilly and Novo, alongside supporting comprehensive care that includes clinical consultation, nutritional guidance, and lifestyle coaching. As many employers currently do not cover GLP-1s for weight loss, Teladoc's initiative aims to address this service gap by providing flexible options that can meet diverse organizational needs, enhance healthcare spending transparency, and improve access to effective obesity treatments for employees. Additionally, new research highlights the effectiveness of ongoing lifestyle support in achieving sustainable weight loss outcomes. The new employer contribution model will be available starting January 1, 2027.
Potential Positives
- Teladoc Health is expanding its Comprehensive Weight Care program, providing employers with new options to affordably offer FDA-approved GLP-1 medications, which addresses a high consumer demand.
- The program allows employers to manage medication costs and coverage more effectively, ensuring better predictability and transparency in healthcare spending.
- New research indicates that sustained engagement in Teladoc Health's programs leads to meaningful long-term weight loss outcomes for participants, showcasing the effectiveness of their services.
- The integration of clinical care with medication access through a single contract simplifies the management process for employers, enhancing Teladoc's value proposition to clients.
Potential Negatives
- Expansion of the Comprehensive Weight Care program may highlight existing gaps in employer coverage for GLP-1 medications, as nearly half of employers currently do not cover them for weight loss.
- The reliance on employers to contribute to medication costs may lead to unpredictable patient out-of-pocket expenses if employers are hesitant or unable to participate, potentially reducing access to necessary treatments.
- The need for employers to manage costs through engagement criteria, like food logging and weigh-ins, could be perceived as intrusive and deter employee participation in the program.
FAQ
What is Teladoc Health's Comprehensive Weight Care program?
Teladoc Health's Comprehensive Weight Care program offers employers access to FDA-approved GLP-1 medications and comprehensive support for weight management.
How do employers manage costs with the new weight care program?
Employers set a fixed payment per employee for medication fills and manage eligibility, oversight, and invoicing through Teladoc Health.
What support do employees receive in the weight care program?
Employees receive access to licensed clinicians, dietitians, health coaches, and tools like digital scales, personalized coaching, and mental health support.
When will the employer contribution option become available?
The employer contribution option is available now, with the first programs launching for clients on January 1, 2027.
What research supports the effectiveness of Teladoc's weight care programs?
Recent research shows sustained participation in weight care programs leads to significant weight loss and improved BMI among members over two years.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TDOC Insider Trading Activity
$TDOC insiders have traded $TDOC stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $TDOC stock by insiders over the last 6 months:
- CHARLES III DIVITA (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 3 sales selling 55,011 shares for an estimated $380,071.
- CARLOS NUENO (President, International) has made 0 purchases and 2 sales selling 35,628 shares for an estimated $318,031.
- KELLY BLISS (President, U.S. Group Health) has made 0 purchases and 4 sales selling 15,179 shares for an estimated $126,067.
- FERNANDO M. RODRIGUES (President of BetterHelp) has made 0 purchases and 2 sales selling 15,249 shares for an estimated $114,131.
- ADAM C VANDERVOORT (CHIEF LEGAL OFFICER, SECRETARY) sold 7,906 shares for an estimated $60,299
- JOSEPH RONALD CATAPANO (Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,592 shares for an estimated $11,811.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TDOC Revenue
$TDOC had revenues of $605.1M in Q3 2026. This is a decrease of -3.41% from the same period in the prior year.
You can track TDOC financials on Quiver Quantitative's TDOC stock page.
You can access data on TDOC stock through the Quiver Quantitative API.
$TDOC Hedge Fund Activity
We have seen 141 institutional investors add shares of $TDOC stock to their portfolio, and 183 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERICAN CENTURY COMPANIES INC added 4,617,419 shares (+94.3%) to their portfolio in Q3 2026, for an estimated $26,781,030
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 3,063,252 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $17,766,861
- BLACKROCK, INC. added 2,511,146 shares (+15.5%) to their portfolio in Q3 2026, for an estimated $14,564,646
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,977,594 shares (-96.9%) from their portfolio in Q3 2026, for an estimated $11,470,045
- PALE FIRE CAPITAL SE removed 1,973,762 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $11,447,819
- DIMENSIONAL FUND ADVISORS LP added 1,728,348 shares (+23.4%) to their portfolio in Q3 2026, for an estimated $10,024,418
- VANGUARD PORTFOLIO MANAGEMENT LLC added 1,579,998 shares (+12.5%) to their portfolio in Q3 2026, for an estimated $9,163,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TDOC Analyst Ratings
Wall Street analysts have issued reports on $TDOC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 11/02/2026
- Canaccord Genuity issued a "Buy" rating on 07/30/2026
To track analyst ratings and price targets for $TDOC, check out Quiver Quantitative's $TDOC forecast page.
$TDOC Price Targets
Multiple analysts have issued price targets for $TDOC recently. We have seen 11 analysts offer price targets for $TDOC in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Charles Rhyee from TD Cowen set a target price of $8.0 on 11/09/2026
- Stan Berenshteyn from Wells Fargo set a target price of $8.0 on 11/05/2026
- Glen Santangelo from Barclays set a target price of $9.0 on 11/04/2026
- Kevin Caliendo from UBS set a target price of $9.0 on 11/02/2026
- Michael Wiederhorn from Oppenheimer set a target price of $10.0 on 11/02/2026
- Lisa Gill from JP Morgan set a target price of $10.0 on 10/30/2026
- David Grossman from Stifel set a target price of $6.5 on 10/29/2026
Full Release
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced an expansion of its Comprehensive Weight Care program that gives employers a new way to offer access to FDA-approved GLP-1 medications and comprehensive weight care while keeping medication spending predictable.
Teladoc Health's Comprehensive Weight Care program now gives employers the option to contribute toward the cost of GLP-1 medications outside of traditional pharmacy benefit designs with flexible patient out of pocket costs. This offering enables employers to help employees and their families pay for authentic FDA-approved GLP-1 medications from Eli Lilly and Company and Novo, alongside comprehensive clinical care, nutrition and lifestyle support.
This option comes as consumer demand for GLP-1s remains high and coverage remains a challenge. According to WTW , nearly half of employers currently do not cover GLP-1s for weight loss.
“Employers want to provide benefits that help their workforce achieve their health goals and need flexible strategies that work for their organizations,” said Kelly Bliss, President, U.S. Group Health at Teladoc Health. “We are helping employers meet the needs of their employees while providing greater predictability and transparency around healthcare spending. Importantly, we give people a trusted path to high-quality care and affordable access to FDA-approved, authentic medication for meaningful, sustained health outcomes.”
“Too many people still lack coverage for obesity care, and Lilly is working to close that access gap,” said Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA. “Lilly Employer Connect gives employers greater choice, control and cost transparency in how they support access for their employees, and we’re pleased Teladoc Health is helping bring that flexibility to its clients.”
“Expanding access to obesity care requires options that work for patients and employers,” said Tom Scales, SVP Market Access and Public Affairs for Novo. “Novo works with approved collaborators like Teladoc to provide pathways specifically designed for employer-funded access, giving employers a clear and predictable way to manage their costs and help their employees afford obesity care.”
Through this offering, employers can offer access to medications from both Lilly and Novo, with multidisciplinary support from licensed obesity medicine clinicians, registered dietitians and health coaches, together with connected digital scales, personalized lifestyle coaching, nutrition counseling,
AI-enabled food logging
, mental health support and behavior-change resources. The care team stays with members over time, providing the ongoing support obesity care requires.
How it works
Employers are now able to manage their program through a single contract with Teladoc Health for both the clinical program and medication access. Each plan year, the employer sets a fixed payment per employee per fill that applies consistently across covered medications, and employees pay the remaining balance for each fill.
Teladoc Health manages eligibility, program oversight, and consolidated employer invoicing. Pharmacy claims are administered on a 100% pass-through basis, including eligibility verification, real-time application of each employer's payment, and audit-ready claims documentation.
Employers see what they pay for each fill, including the medication, the pharmacy dispensing fee, and the claims administration fee. This gives benefits teams the clarity to set a contribution level with confidence and forecast total program spend for the year.
Employers can also choose to tie their contribution to program engagement, using criteria such as food logging, regular weigh-ins, engagement with educational content and ongoing participation in the program to determine eligibility for the employer contribution.
New research reinforces value of sustained lifestyle support
Teladoc Health also unveiled new research that examines two years of weight-loss outcomes among nearly 23,000 members enrolled in its Weight and Diabetes Prevention programs.
The research found that clinically meaningful weight loss increased over time, suggesting that sustained participation and long-term access to comprehensive lifestyle support can help members continue making meaningful progress beyond the first year:
- 47.7% of members achieved at least 5% weight loss by 24 months
- Among members who lost weight during their first year, 53% continued losing additional weight during year two
- Nearly one-third of members achieved weight loss of 10% or greater by 24 months
-
Average BMI declined by 2.3 points, and approximately one in five members moved from an obesity category into either the overweight or healthy BMI range over two years
Additional research, presented at ObesityWeek 2026 in Washington D.C., focused on GLP-1 utilization patterns and its association on weight loss at 12-months and durability of weight loss at 24-months.
The launch is part of Teladoc Health’s strategy to enhance its integrated care offerings and deliver greater value to customers, building on the GLP-1 medication self-pay option that Teladoc Health introduced last year as well as innovations within the Teladoc One care model.
Teladoc Health’s employer contribution option is available now, and the first contracted clients will launch programs for their employees Jan. 1, 2027.
To learn more about Teladoc Health’s obesity and weight care programs, click here .
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at
teladochealth.com.
Media:
Lou Serio
[email protected]
202-569-9715